Financings in Brief: i-Stat
This article was originally published in The Gray Sheet
Executive Summary
i-Stat: Files registration statement with SEC for an offering of 2 mil. shares (2.3 mil. if overallotment options are exercised). Net proceeds from the offering are expected to be approximately $41.8 mil., assuming an offering price of $22.25 per share. The filing says that the funds will be used to "finance the further implementation of [i-Stat's] marketing plans, the expansion of its manufacturing capacity, and the development of new products," as well as for working capital and general corporate purposes. Last year, i-Stat received FDA clearance to market blood gas cartridges on its i-Stat portable blood analyzer ("The Gray Sheet" June 13, 1994, In Brief). The company would have about 13 mil. outstanding shares after the offering. Smith Barney and Goldman, Sachs are underwriting...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.